Chest pain in patients without obstructive coronary artery disease has been realized as a
frequent problem encountered in clinical practice. Invasive flow investigations have …

Cardiovascular disease is the most common cause of death in patients with end-stage renal
disease (ESRD). The initiation of dialysis for treatment of ESRD exacerbates chronic …

In the last decade, myocardial perfusion imaging (MPI) with PET has emerged to play a
pivotal role in the clinical routine process for the detection of hemodynamically significant …

Myocardial ischemia is an established pathophysiological feature of hypertrophic
cardiomyopathy (HCM) that impacts various clinical features, including heart failure (HF) and …

Microvascular dysfunction is responsible for chest pain in various kinds of patients, including
those with obstructive coronary artery disease and persistent symptoms despite …

Hypertrophic cardiomyopathy (HCM) is defined by the presence of left ventricular
hypertrophy in the absence of other potentially causative cardiac, systemic, syndromic, or …

Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy
and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage …

Despite the progress made in risk stratification, sudden cardiac death and heart failure
remain dreaded complications for hypertrophic cardiomyopathy (HCM) patients. Myocardial …

With growing evidence in clinical practice, the understanding of coronary syndromes has
gradually evolved out of focusing on the well-established link between stenosis of epicardial …

Background It is unknown whether sex-specific differences in mortality observed in HCM are
due to older age of women at presentation, or whether women have greater degree of LV …